Loading...

Ascendis Pharma A/S

ASNDNASDAQ
HealthcareBiotechnology
$173.06
$-4.49(-2.53%)

Ascendis Pharma A/S (ASND) Stock Overview

Explore Ascendis Pharma A/S’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
36.34%
36.34%
Profit Growth
$-5.69
21.47%
EPS Growth
$-5.69
23.63%
Operating Margin
-90.54%
38.81%
ROE
191.42%
21.47%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
5
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$175.00
Average$199.18
High$289.00

Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

CEO

Mr. Jan Moller Mikkelsen

Employees

1,017

Headquarters

Tuborg Boulevard 12, Hellerup

Founded

2015

Frequently Asked Questions